These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 526925)
1. Role of cholesterol in enhancing the antitumor activity of cytosine arabinoside entrapped in liposomes. Mayhew E; Rustum YM; Szoka F; Papahadjopoulos D Cancer Treat Rep; 1979; 63(11-12):1923-8. PubMed ID: 526925 [No Abstract] [Full Text] [Related]
2. Effect of cholesterol content on antitumor activity and toxicity of liposome-encapsulated 1-beta-D-arabinofuranosylcytosine in vivo. Ganapathi R; Krishan A; Wodinsky I; Zubrod CG; Lesko LJ Cancer Res; 1980 Mar; 40(3):630-3. PubMed ID: 7471083 [TBL] [Abstract][Full Text] [Related]
3. Role of liposome type and route of administration in the antitumor activity of liposome-entrapped 1-beta-D-arabinofuranosylcytosine against mouse L1210 leukemia. Rustum YM; Dave C; Mayhew E; Papahadjopoulos D Cancer Res; 1979 Apr; 39(4):1390-5. PubMed ID: 421223 [No Abstract] [Full Text] [Related]
4. Use of liposomes for the enhancement of the cytotoxic effects of cytosine arabinoside. Mayhew E; Papahadjopoulos D; Rustum YM; Dave C Ann N Y Acad Sci; 1978; 308():371-86. PubMed ID: 279297 [No Abstract] [Full Text] [Related]
5. Multivesicular liposomes containing cytarabine for slow-release Sc administration. Kim S; Howell SB Cancer Treat Rep; 1987 May; 71(5):447-50. PubMed ID: 3567968 [TBL] [Abstract][Full Text] [Related]
6. [Influencing factors in the leakage of liposome and arabinoside cytosine (ARA-C) entrapped in liposomes in treatment of L1210 mouse leukemia]. Fu NW Zhonghua Zhong Liu Za Zhi; 1985 Jul; 7(4):250-3. PubMed ID: 4085312 [TBL] [Abstract][Full Text] [Related]
7. Enhancement of the cancer chemotherapeutic effect of cytosine arabinoside entrapped in liposomes on mouse leukemia L-1210. Kobayashi T; Tsukagoshi S; Sakurai Y Gan; 1975 Dec; 66(6):719-20. PubMed ID: 1225724 [No Abstract] [Full Text] [Related]
8. Antitumor activity of a water-insoluble compound entrapped in liposomes on L1210 leukemia in mice. Brassinne C; Atassi G; Frühling J; Penasse W; Coune A; Hildebrand J; Ruysschaert JM; Laduron C J Natl Cancer Inst; 1983 Jun; 70(6):1081-6. PubMed ID: 6574278 [TBL] [Abstract][Full Text] [Related]
9. Treatment of murine L1210 lymphoid leukemia and melanoma B16 with lipophilic cytosine arabinoside prodrugs incorporated into unilamellar liposomes. Rubas W; Supersaxo A; Weder HG; Hartmann HR; Hengartner H; Schott H; Schwendener R Int J Cancer; 1986 Jan; 37(1):149-54. PubMed ID: 3941019 [TBL] [Abstract][Full Text] [Related]
10. [Experimental study on the correlation between the antitumor activity and pharmacokinetics of cytosine arabinoside (Ara-C) and N4-behenoyl-1-beta-D-arabinofuranosylcytosine (BH-AC)]. Takenaka T; Kimura K Nihon Gan Chiryo Gakkai Shi; 1985 Dec; 20(10):2322-8. PubMed ID: 3831176 [No Abstract] [Full Text] [Related]
11. Combination chemotherapy with cytosine arabinoside, L-asparaginase, and 6-azauridine for transplantable murine leukemias. Avery TL; Roberts D Cancer Res; 1973 Apr; 33(4):791-9. PubMed ID: 4696479 [No Abstract] [Full Text] [Related]
12. Pharmacokinetics and cellular determinants of response to 1-beta-arabinofuranosylcytosine (ara-C). Riva CM; Rustum YM; Preisler HD Semin Oncol; 1985 Jun; 12(2 Suppl 3):1-8. PubMed ID: 3859925 [No Abstract] [Full Text] [Related]
13. Lipophilic cisplatin analogues entrapped in liposomes: role of intraliposomal drug activation in biological activity. Perez-Soler R; Khokhar AR Cancer Res; 1992 Nov; 52(22):6341-7. PubMed ID: 1423280 [TBL] [Abstract][Full Text] [Related]
14. Effect of different doses of methotrexate (NSC-740), cytosine arabinoside (NSC-63878), and cyclophosphamide (NSC-26271) on drug resistance in mice with L1210 leukemia. Schmid FA; Hutchison DJ Cancer Chemother Rep; 1972 Aug; 56(4):473-81. PubMed ID: 5081590 [No Abstract] [Full Text] [Related]
15. Antitumor activity of prolonged-release derivative of cytosine arabinoside, cytosine arabinoside-agarose conjugate. Hashida M; Kojima T; Muranishi S; Sezaki H Gan; 1978 Dec; 69(6):839-43. PubMed ID: 750275 [TBL] [Abstract][Full Text] [Related]
16. Selective chemotherapy for advanced murine L 1210 leukemia by combination of 2' deoxycytidine and lethal doses of cytosine-arabinoside. Buchman VM; Svet-Maoldavsky GJ; Lichinitser MR; Mkheidze DM Biomedicine; 1977 Jul; 27(5):179-80. PubMed ID: 922116 [TBL] [Abstract][Full Text] [Related]
17. Chemotherapeutic efficacy of Nocodazole encapsulated in liposomes on L1210 murine leukemia. Laduron C; Coune A; Atassi G; Hildebrand J; Ruysschaert JM; Stryckmans P; Brassinne C Res Commun Chem Pathol Pharmacol; 1983 Mar; 39(3):419-36. PubMed ID: 6190203 [TBL] [Abstract][Full Text] [Related]
18. Effect of 3-deazauridine on the metabolism, toxicity, and antitumor activity of azacitidine in mice bearing L1210 leukemia sensitive and resistant to cytarabine. Li ZR; Campbell J; Rustum YM Cancer Treat Rep; 1983 Jun; 67(6):547-54. PubMed ID: 6190558 [TBL] [Abstract][Full Text] [Related]
19. Pharmacology of combination chemotherapy of cytosine arabinoside (ara-C) and uracil arabinoside (ara-U) or tetrahydrouridine (THU) against murine leukemia L1210/0 in tumor-bearing mice. Avramis VI; Powell W Cancer Invest; 1987; 5(4):293-9. PubMed ID: 3664332 [TBL] [Abstract][Full Text] [Related]
20. Recent advances in sustained release of antineoplastic drugs using liposomes which avoid uptake into the reticuloendothelial system. Allen TM; Mehra T Proc West Pharmacol Soc; 1989; 32():111-4. PubMed ID: 2780575 [No Abstract] [Full Text] [Related] [Next] [New Search]